These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24434871)

  • 1. Activity-dependent changes in MAPK activation in the Angelman Syndrome mouse model.
    Filonova I; Trotter JH; Banko JL; Weeber EJ
    Learn Mem; 2014 Jan; 21(2):98-104. PubMed ID: 24434871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology.
    Dindot SV; Antalffy BA; Bhattacharjee MB; Beaudet AL
    Hum Mol Genet; 2008 Jan; 17(1):111-8. PubMed ID: 17940072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult
    Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
    J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
    Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
    Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired hippocampal plasticity and altered neurogenesis in adult Ube3a maternal deficient mouse model for Angelman syndrome.
    Mardirossian S; Rampon C; Salvert D; Fort P; Sarda N
    Exp Neurol; 2009 Dec; 220(2):341-8. PubMed ID: 19782683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
    Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
    Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Angelman syndrome protein Ube3a/E6AP is required for Golgi acidification and surface protein sialylation.
    Condon KH; Ho J; Robinson CG; Hanus C; Ehlers MD
    J Neurosci; 2013 Feb; 33(9):3799-814. PubMed ID: 23447592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Region-specific impairments in striatal synaptic transmission and impaired instrumental learning in a mouse model of Angelman syndrome.
    Hayrapetyan V; Castro S; Sukharnikova T; Yu C; Cao X; Jiang YH; Yin HH
    Eur J Neurosci; 2014 Mar; 39(6):1018-1025. PubMed ID: 24329862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
    Jamal I; Kumar V; Vatsa N; Shekhar S; Singh BK; Sharma A; Jana NR
    Neurobiol Dis; 2017 Sep; 105():99-108. PubMed ID: 28576709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome.
    Su H; Fan W; Coskun PE; Vesa J; Gold JA; Jiang YH; Potluri P; Procaccio V; Acab A; Weiss JH; Wallace DC; Kimonis VE
    Neurosci Lett; 2011 Jan; 487(2):129-33. PubMed ID: 19563863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UBE3A regulates the transcription of IRF, an antiviral immunity.
    Furumai R; Tamada K; Liu X; Takumi T
    Hum Mol Genet; 2019 Jun; 28(12):1947-1958. PubMed ID: 30690483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
    Greer PL; Hanayama R; Bloodgood BL; Mardinly AR; Lipton DM; Flavell SW; Kim TK; Griffith EC; Waldon Z; Maehr R; Ploegh HL; Chowdhury S; Worley PF; Steen J; Greenberg ME
    Cell; 2010 Mar; 140(5):704-16. PubMed ID: 20211139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome.
    Mulherkar SA; Jana NR
    Neurobiol Dis; 2010 Dec; 40(3):586-92. PubMed ID: 20696245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential therapeutic approaches for Angelman syndrome.
    Bi X; Sun J; Ji AX; Baudry M
    Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
    Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
    PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward a Broader View of Ube3a in a Mouse Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and Glial Cells.
    Grier MD; Carson RP; Lagrange AH
    PLoS One; 2015; 10(4):e0124649. PubMed ID: 25894543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards an understanding of Angelman syndrome in mice studies.
    Yang X
    J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
    Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
    Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.
    Lopez SJ; Laufer BI; Beitnere U; Berg EL; Silverman JL; O'Geen H; Segal DJ; LaSalle JM
    Hum Mol Genet; 2019 Nov; 28(22):3842-3852. PubMed ID: 31625566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
    Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
    Mol Autism; 2018; 9():45. PubMed ID: 30140420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.